SG11201805263TA - Compositions and methods for detecting and treating esophageal cancer - Google Patents
Compositions and methods for detecting and treating esophageal cancerInfo
- Publication number
- SG11201805263TA SG11201805263TA SG11201805263TA SG11201805263TA SG11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- esophageal cancer
- compositions
- rule
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307189 | 2015-12-31 | ||
| EP16305139 | 2016-02-05 | ||
| PCT/EP2017/050037 WO2017114976A1 (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating esophageal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805263TA true SG11201805263TA (en) | 2018-07-30 |
Family
ID=57821946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805263TA SG11201805263TA (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating esophageal cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11789021B2 (ko) |
| EP (2) | EP3397967B1 (ko) |
| JP (2) | JP7018885B2 (ko) |
| KR (2) | KR102197478B1 (ko) |
| CN (1) | CN108700589A (ko) |
| AU (2) | AU2017204686B2 (ko) |
| BR (1) | BR112018013272A2 (ko) |
| CA (2) | CA3193481A1 (ko) |
| EA (1) | EA037032B1 (ko) |
| ES (1) | ES2861587T3 (ko) |
| PL (1) | PL3397967T3 (ko) |
| SG (1) | SG11201805263TA (ko) |
| WO (1) | WO2017114976A1 (ko) |
| ZA (1) | ZA201804142B (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019110662A1 (en) * | 2017-12-05 | 2019-06-13 | Progastrine Et Cancers S.À R.L. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
| CN112004560A (zh) | 2017-12-08 | 2020-11-27 | Ecs生物识别系统有限公司 | 癌症诊断中的放射性标记的前胃液素 |
| TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ｅｃｓ前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
| EP3759492A1 (en) * | 2018-02-27 | 2021-01-06 | ECS-Progastrin SA | Progastrin as a biomarker for immunotherapy |
| US20220356532A1 (en) * | 2019-10-24 | 2022-11-10 | The Johns Hopkins University | Compositions and methods for detecting and treating esophageal cancer |
| JP7287532B2 (ja) * | 2020-08-04 | 2023-06-06 | 王子ホールディングス株式会社 | トイレットロール |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
| PL193780B1 (pl) | 1997-04-14 | 2007-03-30 | Micromet Ag | Sposób wytwarzania receptora przeciw ludzkim antygenom, ludzkie przeciwciało i środek farmaceutyczny |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2450898A1 (en) * | 2001-07-09 | 2003-01-23 | Aphton Corporation | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| JP2008513536A (ja) * | 2004-09-22 | 2008-05-01 | レセプター バイオロジックス インコーポレイテッド | プロガストリンに対するモノクローナル抗体 |
| US8278421B2 (en) * | 2006-03-20 | 2012-10-02 | Xoma Techolology Ltd. | Human antibodies specific for gastrin materials and methods |
| WO2008076454A1 (en) * | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| US20110085986A1 (en) | 2009-10-13 | 2011-04-14 | Pomila Singh | Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides |
| US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
| US9487582B2 (en) | 2010-01-08 | 2016-11-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for treating pancreatic cancer |
| US9217032B2 (en) * | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| KR101570404B1 (ko) | 2010-03-24 | 2015-11-20 | 르 라보레또레 쎄르비에르 | 결장직장암 및 위창자암의 예방 |
| KR101576174B1 (ko) | 2010-07-26 | 2015-12-09 | 르 라보레또레 쎄르비에르 | 간암 요법을 위한 방법 및 조성물 |
| CN113514647A (zh) * | 2014-06-13 | 2021-10-19 | 拜奥希特公司 | 胃泌素-17作为具有增加的数种相关后发病风险的萎缩性胃炎的生物标志物的用途 |
| WO2016066671A1 (en) * | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant cancers using progastrin inhibitors |
-
2017
- 2017-01-02 JP JP2018534930A patent/JP7018885B2/ja active Active
- 2017-01-02 CA CA3193481A patent/CA3193481A1/en active Pending
- 2017-01-02 EP EP17700483.5A patent/EP3397967B1/en active Active
- 2017-01-02 CN CN201780013902.0A patent/CN108700589A/zh active Pending
- 2017-01-02 US US16/067,208 patent/US11789021B2/en active Active
- 2017-01-02 EA EA201891527A patent/EA037032B1/ru unknown
- 2017-01-02 CA CA3009785A patent/CA3009785A1/en active Pending
- 2017-01-02 BR BR112018013272A patent/BR112018013272A2/pt not_active IP Right Cessation
- 2017-01-02 KR KR1020187020013A patent/KR102197478B1/ko active IP Right Grant
- 2017-01-02 ES ES17700483T patent/ES2861587T3/es active Active
- 2017-01-02 KR KR1020207037405A patent/KR102430893B1/ko active IP Right Grant
- 2017-01-02 SG SG11201805263TA patent/SG11201805263TA/en unknown
- 2017-01-02 EP EP20217589.9A patent/EP3848709A1/en active Pending
- 2017-01-02 PL PL17700483T patent/PL3397967T3/pl unknown
- 2017-01-02 AU AU2017204686A patent/AU2017204686B2/en active Active
- 2017-01-02 WO PCT/EP2017/050037 patent/WO2017114976A1/en active Application Filing
-
2018
- 2018-06-20 ZA ZA201804142A patent/ZA201804142B/en unknown
-
2020
- 2020-03-31 AU AU2020202296A patent/AU2020202296B2/en active Active
-
2022
- 2022-01-31 JP JP2022013712A patent/JP7363007B2/ja active Active
-
2023
- 2023-09-15 US US18/468,096 patent/US20240085423A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2861587T3 (es) | 2021-10-06 |
| BR112018013272A2 (pt) | 2018-12-11 |
| ZA201804142B (en) | 2019-11-27 |
| EP3397967A1 (en) | 2018-11-07 |
| JP7363007B2 (ja) | 2023-10-18 |
| KR102430893B1 (ko) | 2022-08-09 |
| EA037032B1 (ru) | 2021-01-28 |
| WO2017114976A1 (en) | 2017-07-06 |
| EP3397967B1 (en) | 2020-12-30 |
| JP7018885B2 (ja) | 2022-02-14 |
| EA201891527A1 (ru) | 2019-01-31 |
| AU2017204686B2 (en) | 2020-04-30 |
| EP3848709A1 (en) | 2021-07-14 |
| US20240085423A1 (en) | 2024-03-14 |
| JP2022064969A (ja) | 2022-04-26 |
| PL3397967T3 (pl) | 2021-06-28 |
| KR20180108586A (ko) | 2018-10-04 |
| AU2017204686A1 (en) | 2018-07-05 |
| AU2020202296A1 (en) | 2020-04-23 |
| CA3009785A1 (en) | 2017-07-06 |
| JP2019505785A (ja) | 2019-02-28 |
| KR102197478B1 (ko) | 2021-01-04 |
| CA3193481A1 (en) | 2017-07-06 |
| CN108700589A (zh) | 2018-10-23 |
| AU2020202296B2 (en) | 2022-06-02 |
| US20190011447A1 (en) | 2019-01-10 |
| US11789021B2 (en) | 2023-10-17 |
| KR20210002363A (ko) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805263TA (en) | Compositions and methods for detecting and treating esophageal cancer | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201908998XA (en) | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201805141QA (en) | Compositions and methods for detecting and treating gastric cancer | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407802WA (en) | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy | |
| SG11201408605UA (en) | Methods for biodegradable derivatization of cellulosic surfaces | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201908888VA (en) | Compositions and methods for treating lung cancer | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof |